

Exendin(9-39) amide

Cat. No.:	HY-P0264
CAS No.:	133514-43-9
Molecular Formula:	C ₁₄₉ H ₂₃₄ N ₄₀ O ₄₇ S
Molecular Weight:	3369.76
Sequence:	Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH ₂ <small>DLSKQMEEEAVRLFIEWLKNNGPSSGAPPPS-NH₂</small>
Sequence Shortening:	DLSKQMEEEAVRLFIEWLKNNGPSSGAPPPS-NH ₂
Target:	GCGR
Pathway:	GPCR/G Protein
Storage:	Sealed storage, away from moisture Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 50 mg/mL (14.84 mM); Need ultrasonic				
		Solvent Concentration	Mass		
	Preparing Stock Solutions		1 mg	5 mg	10 mg
		1 mM	0.2968 mL	1.4838 mL	2.9676 mL
		5 mM	0.0594 mL	0.2968 mL	0.5935 mL
	10 mM	0.0297 mL	0.1484 mL	0.2968 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (29.68 mM); Clear solution; Need ultrasonic				

BIOLOGICAL ACTIVITY

Description	Avexitide (Exendin (9-39)) is a specific and competitive GLP-1 receptor antagonist.
In Vitro	GLP-1 plays a role in the control of fasting glucose. Avexitide (Exendin (9-39)), a truncated form of the GLP-1 agonist exendin-4, is a specific GLP-1 receptor antagonist ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Continuous subcutaneous infusion of Avexitide (Exendin (9-39)) significantly raises fasting blood glucose levels in SUR-1 ^{-/-} mice without affecting glucose tolerance ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration ^[2]

Mice^[2]

Alzet miniosmotic pumps are implanted subcutaneously to deliver Avexitide (Exendin (9-39)) at a rate of 150 pmol/kg/min or vehicle (0.9% NaCl, 1% bovine serum albumin) for 2 weeks^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- J Headache Pain. 2021 Jul 29;22(1):86.
- Br J Pharmacol. 2020 Aug;177(15):3389-3402.
- Life Sci. 2022 Apr 1;294:120370.
- Diabetes Obes Metab. 2022 Jul;24(7):1255-1266.
- MAbs. Jan-Dec 2021;13(1):1893425.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Calabria AC, et al. GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital owing to inactivating mutations in the ATP-sensitive K⁺ channel. Diabetes. 2012 Oct;61(10):2585-91.

[2]. De León DD, et al. Exendin-(9-39) corrects fasting hypoglycemia in SUR-1^{-/-} mice by lowering cAMP in pancreatic beta-cells and inhibiting secretion. J Biol Chem. 2008 Sep 19;283(38):25786-93.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA